Drugs for Milker's Nodule (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 62)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Vaccines |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 2 |
|
Immunologic Factors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 3 |
|
Immunoglobulins, Intravenous |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 4 |
|
Antibodies |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 5 |
|
Rho(D) Immune Globulin |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 6 |
|
gamma-Globulins |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 7 |
|
Immunoglobulins |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 8 |
|
Sorafenib |
Approved, Investigational |
Phase 3,Phase 2 |
|
284461-73-0 |
216239
406563
|
|
Synonyms:
284461-73-0
4-(4-((((4-chloro-3-(Trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-Trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(Trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafénib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
| 9 |
|
Cantharidin |
Approved, Investigational |
Phase 3,Phase 2,Not Applicable |
|
56-25-7 |
|
|
Synonyms:
1,2-Dimethyl-3,6-epoxyperhydrophthalic anhydride
Cantharidine
Cantharone
|
exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride
Kantharidin
|
|
| 10 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3,Phase 3,Phase 1 |
|
|
|
| 11 |
|
Protein Kinase Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
| 12 |
|
Angiogenesis Inhibitors |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
| 13 |
|
Iron-Dextran Complex |
|
Phase 3 |
|
|
|
| 14 |
|
Sargramostim |
Approved, Investigational |
Phase 2,Phase 1 |
|
123774-72-1, 83869-56-1 |
|
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
| 15 |
|
Phenol |
Approved, Experimental |
Phase 2 |
|
108-95-2 |
996
|
|
Synonyms:
Acide carbolique
Acide phenique
Acide phénique
Anbesol
Benzenol
Benzophenol
campho-Phenique cold sore gel
campho-Phenique gel
campho-Phenique liquid
Carbol
Carbolate
Carbolic acid
Carbolic acid liquid
Carbolic oil
Carbolicum acidum
Carbolsaeure
Carbolsaure
Carbolsäure
Cepastat lozenges
Cuticura pain relieving ointment
Fenol
Fenolo
Fenosmolin
Fenosmoline
Hydroxybenzene
Hydroxy-benzene
IPH
IZAL
Karbolsaeure
Karbolsäure
Liquefied phenol
Liquid phenol
Liquified phenol
Monohydroxy benzene
|
Monohydroxybenzene
Monophenol
Oxybenzene
Paoscle
Phenate
Phenic
Phenic acid
Phenic Acid
Phenic alcohol
Phenol
Phenol alcohol
Phenol homopolymer
Phenol liquid
Phenol molten
Phenol polymer-bound
Phenol solution
Phenol synthetic
Phenol, sodium salt
Phenolate sodium
Phenolate, sodium
Phenolated water
Phenolated water for disinfection
Phenole
Phenosmolin
Phenyl alcohol
Phenyl hydroxide
Phenylate
Phenylic acid
Phenylic Acid
Phenylic alcohol
PHOH
Sodium phenolate
Synthetic phenol
Tea polyphenol
|
|
| 16 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
100286-90-6, 97682-44-5 |
60838
|
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
| 17 |
|
Oxaliplatin |
Approved, Investigational |
Phase 1, Phase 2 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 18 |
|
Cetuximab |
Approved |
Phase 1, Phase 2 |
|
205923-56-4 |
56842117
2333
|
|
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
|
|
| 19 |
|
Metronidazole |
Approved |
Phase 2,Phase 1 |
|
443-48-1 |
4173
|
|
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitro-1-imidazoleethanol
2-methyl-5-nitroimidazole-1-ethanol
2-Methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
Acromona
AKOS000269646
Anagiardil
APMN
Apo-Metronidazole
Arilin
ARONIS24285
Atrivyl
BAS 02983617
BAY-5360
Bayer 5360
BCBcMAP01_000184
Bexon
BIDD:GT0107
Bio-0694
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
CAS-443-48-1
Caswell No. 579AA
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
Clont
CONT
CPD000058175
D00409
Danizol
DB00916
Deflamon
Deflamon-wirkstoff
DivK1c_000007
Efloran
EINECS 207-136-1
Elyzol
Entizol
EPA Pesticide Chemical Code 120401
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl I.V.
Flagyl I.V. RTU
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
giniflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
Hydrochloride, metronidazole
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
Metric
Metric 21
Metro Cream
Metro Gel
METRO I.V
|
Metro I.V.
Metro I.V. In Plastic Container
MetroCream
Metrodzhil
MetroGel
MetroGel-Vaginal
Metrogel-vaginal (TN)
Metrogyl
Metrolag
MetroLotion
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
metronidazole
Metronidazole
Métronidazole
Metronidazole (JP15/USP/INN)
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole benzoate
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole in Plastic Container
Metronidazole monohydrochloride
Metronidazole Monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazole Phosphoester
METRONIDAZOLE USP
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MLS000028590
MLS000758286
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
neo-Tric
NIDA
Nidagel
NINDS_000007
Noritate
Noritate (TN)
Novonidazol
NSC 50364
NSC 69587
NSC50364
NSC-50364
NSC69587
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
Prestwick_334
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Protostat
Rathimed
Rosased
RP 8823
RP-8823
S1907_Selleck
SAM001247010
Sanatrichom
Satric
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
Spectrum_001035
SPECTRUM1500412
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
STK177359
Takimetol
Trichazol
Trichex
Tricho cordes
Trichocide
Tricho-gynaedron
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
Wagitran
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Zadstat
ZERO/004064
Zidoval
ZINC00113442
|
|
| 20 |
|
Bicalutamide |
Approved |
Phase 2 |
|
90357-06-5 |
2375
56069
|
|
Synonyms:
(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide
4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
4'-cyano-3-(4-Fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
90357-06-5
AC1L1DJE
AC-4232
Astra brand of bicalutamide
Astra brand OF bicalutamide
AstraZeneca brand of bicalutamide
AstraZeneca brand OF bicalutamide
Bicalutamida
bicalutamide
Bicalutamide
Bicalutamide (JAN/USP/INN)
Bicalutamide [USAN:INN:BAN]
Bicalutamidum
BRN 5364666
C053541
C08160
C18H14F4N2O4S
Casodex
Casodex (TN)
Casodex, Cosudex, Calutide, Kalumid, Bicalutamide
CHEMBL409
CID2375
Cosudex
CPD000466329
D00961
|
DB01128
FT-0080576
HMS2051B13
HMS2089N12
I06-0475
I06-0480
ICI 176334
ICI-176334
KS-1161
LS-119125
MLS000759437
MLS001424047
MolPort-003-845-034
MolPort-006-808-679
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
NCGC00167977-01
NCGC00167977-02
NSC722665
Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,
propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-)
Raffolutil
S1190_Selleck
SAM001246612
SMR000466329
TL8005814
Zeneca brand of bicalutamide
Zeneca brand OF bicalutamide
|
|
| 21 |
|
Goserelin |
Approved |
Phase 2 |
|
65807-02-5 |
5311128
47725
|
|
Synonyms:
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
AC1NSK1T
Acetate, goserelin
CID5311128
goserelin
Goserelin
Goserelin acetate
Goserelina
|
HMS2089D16
HS-2015
ICI 118
ICI-118630
ICI-118630Zoladex
MolPort-006-823-831
ZD-9393
Zoladex
|
|
| 22 |
|
Bevacizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
| 23 |
|
Liver Extracts |
|
Phase 2,Phase 1 |
|
|
|
| 24 |
|
Immunoglobulin G |
|
Phase 2,Phase 1 |
|
|
|
| 25 |
|
topoisomerase I inhibitors |
|
Phase 1, Phase 2 |
|
|
|
| 26 |
|
Cola |
|
Phase 1, Phase 2,Phase 2 |
|
|
|
| 27 |
|
Topoisomerase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
| 28 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
| 29 |
|
Hormones |
|
Phase 2 |
|
|
|
| 30 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
| 31 |
|
Androgens |
|
Phase 2 |
|
|
|
| 32 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 2 |
|
|
|
| 33 |
|
Anti-Infective Agents |
|
Phase 2,Phase 1 |
|
|
|
| 34 |
|
Anti-Bacterial Agents |
|
Phase 2,Phase 1 |
|
|
|
| 35 |
|
Antiparasitic Agents |
|
Phase 2,Phase 1 |
|
|
|
| 36 |
|
Androgen Antagonists |
|
Phase 2 |
|
|
|
| 37 |
|
Antiprotozoal Agents |
|
Phase 2,Phase 1 |
|
|
|
| 38 |
|
Angiogenesis Modulating Agents |
|
Phase 1, Phase 2 |
|
|
|
| 39 |
|
Antineoplastic Agents, Immunological |
|
Phase 1, Phase 2 |
|
|
|
| 40 |
|
Cisplatin |
Approved |
Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 41 |
|
Cemiplimab |
Approved, Investigational |
Phase 1 |
|
1801342-60-8 |
|
|
Synonyms:
|
| 42 |
|
Lactitol |
Investigational |
Phase 1 |
|
585-88-6, 585-86-4 |
493591
|
|
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
lactitol
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
| 43 |
|
Adjuvants, Immunologic |
|
Phase 1 |
|
|
|
| 44 |
|
MF59 oil emulsion |
|
Phase 1 |
|
|
|
| 45 |
|
Laxatives |
|
Phase 1 |
|
|
|
| 46 |
|
Poly I-C |
|
Phase 1 |
|
|
|
| 47 |
|
Antiviral Agents |
|
Phase 1 |
|
|
|
| 48 |
|
Gastrointestinal Agents |
|
Phase 1 |
|
|
|
| 49 |
|
Poly ICLC |
|
Phase 1 |
|
|
|
| 50 |
|
Carboxymethylcellulose Sodium |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 123)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV |
Recruiting |
NCT02443623
|
Phase 4 |
|
| 2 |
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat |
Completed |
NCT02474589
|
Phase 3 |
tecovirimat |
| 3 |
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers |
Completed |
NCT01317238
|
Phase 3 |
smallpox vaccine CJ-50300 |
| 4 |
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV |
Completed |
NCT01158157
|
Phase 3 |
|
| 5 |
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects |
Completed |
NCT01144637
|
Phase 3 |
|
| 6 |
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers |
Completed |
NCT01056770
|
Phase 3 |
smallpox vaccine CJ-50300 |
| 7 |
Safety and Efficacy of CJ-50300 in Healthy Volunteers |
Completed |
NCT00607243
|
Phase 2, Phase 3 |
|
| 8 |
A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses |
Completed |
NCT01143181
|
Phase 2, Phase 3 |
CMX001 |
| 9 |
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum |
Completed |
NCT01348386
|
Phase 2, Phase 3 |
Hydroxide Potassium;Placebo |
| 10 |
IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo |
Recruiting |
NCT02977715
|
Phase 3 |
|
| 11 |
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone |
Recruiting |
NCT02562755
|
Phase 3 |
Sorafenib |
| 12 |
Cantharidin Application in Molluscum Patients |
Active, not recruiting |
NCT03377803
|
Phase 3 |
VP-102;Placebo |
| 13 |
Cantharidin Application in Molluscum Patients-1 |
Active, not recruiting |
NCT03377790
|
Phase 3 |
VP-102;Placebo |
| 14 |
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® |
Active, not recruiting |
NCT01913353
|
Phase 3 |
|
| 15 |
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial |
Not yet recruiting |
NCT03699124
|
Phase 3 |
|
| 16 |
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) |
Not yet recruiting |
NCT03927716
|
Phase 3 |
SB206 12%;Placebo |
| 17 |
A Phase 3 Randomized, Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE2) |
Not yet recruiting |
NCT03927703
|
Phase 3 |
SB206 12%;Placebo |
| 18 |
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers |
Unknown status |
NCT00103584
|
Phase 1, Phase 2 |
|
| 19 |
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults |
Completed |
NCT00258947
|
Phase 2 |
|
| 20 |
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® |
Completed |
NCT01827371
|
Phase 2 |
|
| 21 |
Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) |
Completed |
NCT01705223
|
Phase 2 |
|
| 22 |
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects |
Completed |
NCT01668537
|
Phase 2 |
|
| 23 |
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer |
Completed |
NCT01636284
|
Phase 2 |
|
| 24 |
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally |
Completed |
NCT00914732
|
Phase 2 |
|
| 25 |
High Dose IMVAMUNE® in Vaccinia-Naive Individuals |
Completed |
NCT00879762
|
Phase 2 |
Placebo |
| 26 |
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects |
Completed |
NCT00857493
|
Phase 2 |
|
| 27 |
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees |
Completed |
NCT00686582
|
Phase 2 |
|
| 28 |
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine |
Completed |
NCT00466245
|
Phase 2 |
MVA Smallpox vaccine;Placebo |
| 29 |
MVA Post-Event: Administration Timing and Boost Study |
Completed |
NCT00437021
|
Phase 1, Phase 2 |
Placebo (subcutaneous);Placebo (scarification) |
| 30 |
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNEâ„¢) Smallpox Vaccine in Healthy Subjects |
Completed |
NCT00316524
|
Phase 2 |
|
| 31 |
Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. |
Completed |
NCT00189956
|
Phase 2 |
|
| 32 |
ACAM 3000 MVA at Harvard Medical School |
Completed |
NCT00133575
|
Phase 1, Phase 2 |
|
| 33 |
Evaluation and Treatment of Eye Complications of Vaccinia Vaccination |
Completed |
NCT00081835
|
Phase 2 |
NP-016 Vaccine Immune Globulin (IV-VIG) |
| 34 |
Dressing Preparations for Smallpox |
Completed |
NCT00063856
|
Phase 1, Phase 2 |
|
| 35 |
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination |
Completed |
NCT00053495
|
Phase 2 |
|
| 36 |
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults |
Completed |
NCT00053482
|
Phase 2 |
|
| 37 |
APSV in Vaccinia Naive Adults |
Completed |
NCT00050518
|
Phase 2 |
|
| 38 |
Expanded Dryvax Dilution Study in Previously Vaccinated Adults |
Completed |
NCT00050505
|
Phase 2 |
|
| 39 |
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT |
Completed |
NCT00038987
|
Phase 1, Phase 2 |
|
| 40 |
Dryvax Dilution-Prev Vacc Adults |
Completed |
NCT00032708
|
Phase 2 |
|
| 41 |
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults |
Completed |
NCT00026611
|
Phase 2 |
|
| 42 |
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum |
Completed |
NCT03436615
|
Phase 2 |
SB206 4%;SB206 8%;SB206 12%;Placebo |
| 43 |
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. |
Completed |
NCT03186378
|
Phase 2 |
VP-102 |
| 44 |
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum |
Completed |
NCT03077750
|
Phase 2 |
VBP-245 Topical Gel;Vehicle |
| 45 |
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 |
Completed |
NCT03017846
|
Phase 2 |
Cantharidin |
| 46 |
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum |
Completed |
NCT02665260
|
Phase 2 |
Cantharidin;Placebo |
| 47 |
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis |
Completed |
NCT01443260
|
Phase 1, Phase 2 |
|
| 48 |
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection |
Completed |
NCT02038881
|
Phase 2 |
|
| 49 |
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma |
Completed |
NCT01394939
|
Phase 1, Phase 2 |
Irinotecan |
| 50 |
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib |
Completed |
NCT01387555
|
Phase 2 |
|
|
